Navigation Links
Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
Date:3/14/2013

NEW YORK, March 14, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur , the Company's Chief Executive Officer, will be presenting at the upcoming 25th Annual ROTH Conference, to be held March 17th -20th in Dana Point, California.  Mr. Bentsur's presentation is scheduled to take place on Monday, March 18th, at 10:00 AM PT (1:00 PM ET). 

A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Keryx has completed a U.S.-based Phase 3 clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA, and Keryx expects to submit a New Drug Application with the FDA in the second quarter of 2013 and a Marketing Authorization Application with the EMA in mid-2013.  Zerenex is also in Phase 2 development in the U.S. for the management of phosphorus and iron deficiency in anemic patients with Stages 3 to 5 non-dialysis dependent chronic kidney disease.  In addition, Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. has filed its New Drug Application for marketing approval of ferric citrate in Japan for the treatment of hyperphosphatemia in patients with chronic kidney disease.  Keryx is headquartered in New York City.

KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
3. Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
4. Keryx Biopharmaceuticals to Present at The 7th Annual JMP Securities Healthcare Conference
5. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
7. Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Presentation Scheduled for Monday, February 11th at 2:30 PM ET
8. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
9. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
10. Global Biopharmaceuticals Market 2011-2015
11. Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2020)... ... , ... QCDx , a private biotech company that has developed a ... the sale of the proprietary RareScope™ instrument to the Carole and Ray Neag Comprehensive ... research. , “The RareScope can detect and isolate intact and live Circulating Tumor Cells ...
(Date:1/10/2020)... (PRWEB) , ... January 09, 2020 , ... ... and expert services, today announced the acquisition of Cunesoft, a move that expands ... the business objectives of life sciences companies. , Based in Munich, Germany, Cunesoft ...
(Date:1/8/2020)... , ... January 08, 2020 , ... ... wire composites that can achieve specific properties for use in harsh environments inside ... Wire combines up to three metals or alloys to achieve specific properties ...
(Date:1/7/2020)... ... January 07, 2020 , ... ... today announced the launch of its VivopureX™ recombinant mouse antibodies for in vivo ... obtained from rats or hamsters, which Absolute Antibody has engineered into mouse-anti-mouse recombinant ...
Breaking Biology Technology:
(Date:1/24/2020)... ... 24, 2020 , ... The Rockies Venture Club and Colorado ... early-stage bioscience companies in the state. , “Colorado has a world-class ... they need to innovate and grow. This program will mobilize capital within ...
(Date:1/22/2020)... (PRWEB) , ... January 21, 2020 , ... ... Pozil to lead the company’s new Business Development Department. The move, which is ... Pozil had been previously serving as the company’s Senior Vice President where he ...
(Date:1/7/2020)... (PRWEB) , ... January 07, 2020 , ... ... prospectus. The Lifecycle prospectus features not just part numbers like what can be ... facilities, the industries it supports, and that is all linked to the impact ...
Breaking Biology News(10 mins):